Hertl M - Search Results

1

S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update.

Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski HD, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M. Schmidt E, et al. Among authors: hertl m. J Dtsch Dermatol Ges. 2020 May;18(5):516-527. doi: 10.1111/ddg.14097_g. J Dtsch Dermatol Ges. 2020. PMID: 32413222 German. No abstract available.

2

Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.

Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudlo C, Pawelczyk B, Messmer EM, Schuhmann M, Sinkgraven R, Büchner L, Büdinger L, Pfeiffer C, Sticherling M, Hertl M, Kaiser HW, Meurer M, Zillikens D, Messer G. Rzany B, et al. Among authors: hertl m. Arch Dermatol. 2002 Jul;138(7):903-8. doi: 10.1001/archderm.138.7.903. Arch Dermatol. 2002. PMID: 12071817

3

[Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group].

Mayrshofer F, Hertl M, Sinkgraven R, Sticherling M, Pfeiffer C, Zillikens D, Messer G, Rzany Für Die Deutschebsd-Studiengruppe B. Mayrshofer F, et al. Among authors: hertl m. J Dtsch Dermatol Ges. 2005 Jun;3(6):431-5. doi: 10.1111/j.1610-0387.2005.05722.x. J Dtsch Dermatol Ges. 2005. PMID: 15892845 German.

4

[The use of high dose intravenous immunoglobulins in dermatology].

Enk A, Hertl M, Messer G, Meurer M, Rentz E, Zillikens D. Enk A, et al. Among authors: hertl m. J Dtsch Dermatol Ges. 2003 Mar;1(3):183-90. doi: 10.1046/j.1610-0387.2003.02028.x. J Dtsch Dermatol Ges. 2003. PMID: 16285493 German.

5

Autoimmune bullous disorders.

Eming R, Hertl M; Autoimmune Diagnostics Working Group. Eming R, et al. Among authors: hertl m. Clin Chem Lab Med. 2006;44(2):144-9. doi: 10.1515/CCLM.2006.027. Clin Chem Lab Med. 2006. PMID: 16475898 Free article. Review.

6

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.

Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M. Eming R, et al. Among authors: hertl m. Dermatology. 2006;212(2):177-87. doi: 10.1159/000090659. Dermatology. 2006. PMID: 16484825

7

T cell control in autoimmune bullous skin disorders.

Hertl M, Eming R, Veldman C. Hertl M, et al. J Clin Invest. 2006 May;116(5):1159-66. doi: 10.1172/JCI28547. J Clin Invest. 2006. PMID: 16670756 Free PMC article. Review.

8

IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris.

Müller R, Svoboda V, Wenzel E, Gebert S, Hunzelmann N, Müller HH, Hertl M. Müller R, et al. Among authors: hertl m. Exp Dermatol. 2006 Aug;15(8):606-14. doi: 10.1111/j.1600-0625.2006.00451.x. Exp Dermatol. 2006. PMID: 16842599

9

Immunoadsorption in pemphigus.

Eming R, Hertl M. Eming R, et al. Among authors: hertl m. Autoimmunity. 2006 Nov;39(7):609-16. doi: 10.1080/08916930600972040. Autoimmunity. 2006. PMID: 17101505 Review.

10

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).

Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Niedermeier A, et al. Among authors: hertl m. Arch Dermatol. 2007 Feb;143(2):192-8. doi: 10.1001/archderm.143.2.192. Arch Dermatol. 2007. PMID: 17309999

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

502 results

Search Page